Phase 4 N=20 The Impact of Contact Lens Coefficient of Friction (CoF) on the Development of Lid Wiper Epitheliopathy (LWE)
Lid Wiper Epitheliopathy
Primary: Lid Wiper Epitheliopathy — 0.63; 0.25 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=19 Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease
Dry Eye
Primary: Non-invasive Tear Break up Time (TBUT) — 3.9; 4.0 seconds
Phase 4 N=30 Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
Dry Eye
Primary: Efficacy of Lifitegrast Ophthalmic Solution 5% in Treating the Symptoms of Dry Eye in Contact Lens Wearers as Measured by Change in Total CLDEQ-8 Score From Baseline to…
N/A N=55 Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Meibomian Gland Dysfunction · Dry Eye
Primary: Mean Change in Meibomian Gland Score From Baseline at 3 Months — 12.4; 1.4 units on a scale — p=<0.0001
N/A N=30 Impact of Soft Contact Lenses on Lid-Parallel Conjunctival Folds
Lid-Parallel Conjunctival Folds
Primary: Lid-Parallel Conjunctival Folds (LIPCOF) — 1.95; 1.75; 1.70; 1.40 Score
N/A N=35 A Clinical Study of Systane® Lid Wipes in Brazil
Ocular Tolerance · Skin Tolerance
Primary: Number of Participants With a Contact-dermatitis Adverse Reaction — 0 participants
Phase 3 N=50 Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
Chalazion · Dry Eye Syndromes
Primary: Association Between Screening Methods (Meibomian Gland Expression) and Treatment Effectiveness Outcomes (Total Meibomian Gland Score) — 0.4816 Correlation coefficient…
N/A N=26 Mechanisms of Light-based Therapies for Dry Eye Disease
Dry Eye Syndromes · Meibomian Gland Dysfunction
Primary: Change From Baseline in Non-invasive Tear Break Up Time to the Final Follow-up 3 Months After Final Treatment Session — -2.61; -0.85 seconds
N/A N=69 The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction
Meibomian Gland Dysfunction
Primary: Tear Film Breakup Time — 4.65; 4.42 seconds — p=0.550
Phase 4 N=81 Artificial Tears, Tear Lipids and Tear Film Dynamics
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
Phase 4 N=218 Daily Wear Corneal Infiltrative Event Study
Myopia · Hyperopia · Corneal Infiltrative Events
Primary: Number of Participants Developing a Corneal Inflammatory Event (CIE) — 6; 7 participants
N/A N=139 Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye
Chalazion · Dry Eye Syndromes
Primary: Meibomian Gland Assessment (Total Meibomian Gland Secretion Score) — 6.3; 5.6; 14.3; 6.1 Scores on a scale
Phase 4 N=19 Tear Lipid Layer Thickness With Emollient Eye Drops
Dry Eye Syndromes
Primary: Change in Tear Lipid Layer Thickness — 4.8; 8.8 nm
N/A N=144 Formula Identification (FID) 114657 in Contact Lens Wearers
Refractive Error
Primary: Mean Pre-lens Tear Lipid Layer Thickness After 2 Hours of Lens Wear on Day 1 — 61.2; 61.5 ICU
Phase 2 N=150 IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Schirmer's — 1.3; 2.1; 0.9 mm
Phase 2 N=205 Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
Blepharitis
Primary: Change From Baseline in Ocular Discomfort — -4.1; -2.4 score on a scale
N/A N=10 Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax
Sjogren's Disease
Primary: Ocular Surface Temperature of Both Eyes — 33.95; 34.3; 33.93; 33.95 degrees celcius
N/A N=35 Comparison of Lipiflow®-Treatment and a Standard Lid Hygiene Regime
Meibomian Gland Dysfunction
Primary: Change of Dry Eye Symptoms — 40.1; 46.2; 39.7; 15.9 units on a scale
Phase 2 N=102 Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
Keratoconjunctivitis Sicca
Primary: Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4 — -1.3; -1.7; -1.3 units on a scale — p=0.6199
Phase 2 N=213 LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease
Dry Eye
Primary: Mean Change From Baseline in Global Ocular Discomfort Score at Day 71 — -7.9; -3.6 units on a scale
N/A N=400 An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusis (LASIK) Therapy
Dry Eye Syndromes
Primary: Percentage of Patients in Each Category of the Dry Eye Workshop Severity (DEWS) Scale — 65.0; 29.0; 4.2; 1.8 Percentage of Patients
N/A N=26 SYSTANE® Family - Meibomian Deficiency
Dry Eye Syndrome
Primary: Number of Meibomian Glands Yielding Liquid Secretion (MGLYS) — 3.5; 4.2; 7.0; 3.9 functioning glands
N/A N=20 Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea
Ocular Rosacea · Dry Eye
Primary: Change in Ocular Surface Disease Index (OSDI) Symptom Survey Score — -25.9; -2.0 percentage of change in OSDI score — p=0.0312
N/A N=25 Ocular Effects of Scleral Lens Wear on Dry Eye Patients
Dry Eye
Primary: Mean Corneal Thickness — 570.54; 560.73 microns — p=0.25
Phase 4 N=82 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Change From Baseline in Global Ocular Staining Score at Day 35 — 5.4; 5.9; -1.8; -1.8 Number on a scale (score)
Phase 4 N=37 The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED
Dry Eye Disease
Primary: IVCM for Density of Corneal Immune Dendritiform Cells — 9.47; 28.60 cells/mm^2
Phase 4 N=42 The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers
Dry Eye
Primary: Difference in Contact Lens-related Discomfort at 12 Weeks Compared to Baseline — 71; 11 score on a scale — p=<0.01
N/A N=65 Study of the Cell Response in the Tear Film After Overnight Contact Lens Wear
White Blood Cells
Primary: Leukocyte Population — 583187; 420345; 738140 Leukocytes
Phase 3 N=711 A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)
Dry Eye Disease
Primary: Change From Baseline in Patient-Reported Eye Dryness Score to Day 84 — 69.0; 68.3; -30.7; -37.9 units on a scale — p==0.0007
Phase 2 N=10 A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
Persistent Corneal Epithelial Defect
Primary: Percentage of Patients Achieving Corneal Healing (<0.5 mm2 Lesion Size) of the Persistent Corneal Epithelial Defect at 4 Weeks — 5 Participants